Castration-Resistant Prostate Cancer: Mechanisms, Targets, and Treatment. (5th March 2012)

• Record Type: Journal Article
• Authors: Amaral, Teresa Maria Santos; Macedo, Daniela; Fernandes, Isabel; Costa, Luis
• Other Names: Dahut William L. Academic Editor.
• Is Part Of: Prostate cancer. Volume 2012(2012)
• Publication Date: 2012-03-05
• Subjects: Prostate -- Cancer -- Periodicals; Prostate -- Cancer -- Surgery -- Periodicals; 616.99463
• DOI: 10.1155/2012/327253
• Languages: English
• ISSNs: 2090-3111

Abstract

Abstract : Patients with castration-resistant prostate cancer (CRPC), who progress after docetaxel therapy, had until very recently, only a few therapeutic options. Recent advances in this field brought about new perspectives in the treatment of this disease. Molecular, basic, and translational research has given us a better understanding on the mechanisms of CRPC. This great investment has turned into a more rational approach to the development of new drugs. Some of the new treatments are already available to our patients outside clinical trials and may include inhibitors of androgen biosynthesis; new chemotherapy agents; bone-targeted therapy; and immunotherapy. This paper aims to review the mechanisms of prostate cancer resistance, possible therapeutic targets, as well as new options to treat CRPC.